We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 06, 2021

No PFS Benefit of Paclitaxel + Reparixin in Metastatic TNBC

Breast Cancer Research and Treatment


Additional Info

Disclosure statements are available on the authors' profiles:

Breast Cancer Research and Treatment
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
Breast Cancer Res Treat 2021 Sep 03;[EPub Ahead of Print], LJ Goldstein, M Mansutti, C Levy, JC Chang, S Henry, I Fernandez-Perez, J Prausovà, E Staroslawska, G Viale, B Butler, S McCanna, PA Ruffini, MS Wicha, AF Schott

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading